C-EMZSVandria
small molecules, mitophagy, mitochondrial function
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EMZS
C-EMZSC-EMZSsmall molecules, mitophagy, mitochondrial function
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Precision Medicine Revolutionizes Healthcare with Genomics and Personalized Care | Prof. Dr. Ingrid Vasiliu-Feltes posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl … for Research on Aging American Federation for Aging Research Public Investment Fund (PIF) KAUST (King Abdullah University of Science and Technology) King Abdulaziz City for Science and Technology (KACST) King Faisal Specialist Hospital and Research Center King Fahad Medical City - KFMC FII Institute King Abdullah International Medical Research Center (كيمارك KAIMRC) Rubedo Life Sciences Tune Therapeutics Vandria SA Aeovian Pharmaceuticals Albert Einstein College of Medicine … for Research on Aging American Federation for Aging Research Public Investment Fund (PIF) KAUST (King Abdullah University of Science and Technology) King Abdulaziz City for Science and Technology (KACST) King Faisal Specialist Hospital and Research Center King Fahad Medical City - KFMC FII Institute King Abdullah International Medical Research Center (كيمارك KAIMRC) Rubedo Life Sciences Tune Therapeutics Vandria SA Aeovian Pharmaceuticals Albert Einstein College of Medicine … for Research on Aging American Federation for Aging Research Public Investment Fund (PIF) KAUST (King Abdullah University of Science and Technology) King Abdulaziz City for Science and Technology (KACST) King Faisal Specialist Hospital and Research Center King Fahad Medical City - KFMC FII Institute King Abdullah International Medical Research Center (كيمارك KAIMRC) Rubedo Life Sciences Tune Therapeutics Vandria SA Aeovian Pharmaceuticals Albert Einstein College of Medicine
More Than 300 Lobbyists for Industrial Agriculture Attend COP30 - DeSmog --> Skip to content DeSmog International US UK Facebook-f X-twitter Subscribe Donate Donate Donate DeSmog Donate News Energy Science Denial Ad & PR Social Justice Agriculture Politics and Policy False Solutions Activism Canada Finance Opinion & Analysis All Articles Databases Climate Disinformation Agribusiness Ad & PR Koch Network Air Pollution Lobbying Series 2025 COP30 Climate Summit Tech vs. Climate Inside MAGA’s Global Climate Agenda Ad & PR Greenwashing Climate Change Lawsuits History Lessons Mul … ame --> Email Address What content do you want to subscribe to? (check all that apply) All US UK Sign Up By Rachel Sherrington and Nina Lakhani Rachel is an investigative researcher and reporter based in Brussels. Her work has been covered by outlets including The Guardian, Vice News, The Financial Times and The Hill. Nina Lakhani is a senior reporter with the Guardian, covering the intersection between the climate crisis, human rights, structural inequalities, war,
Life Science Career Day Skip to the content Life Science Career Day Venue Date and venue Past Editions Program 2026 Program overview Special Guests | 2026 Careers in sciences: networking and orientation session Companies & organizations, services & large-scale workshop Get the most out of the event 14th life Science Career Day / Summary of the Day and Photo Gallery Program 2025 Program overview Special Guests | 2025 Companies and Organizations | 2025 Alumni and Invited Speakers | 2025 Summary and gallery 2025 Program 2024 Program overview Companies & Organizations – 2024 Alum … SwissTech Convention Center in Lausanne (six-time winner of the Swiss Location Award). Target Audience Students & early-career researchers from Swiss Universities wishing to prepare for a career in the corporate world/industry or in public service and non-governmental organizations. Take a look at the 2026 program (The program for the 2027 edition will be revealed in due course) Inspiring keynote: Dr. Galyna Pidpruzhnykova’s journey from neuroscience to psychedelic
THANK YOU, Danny Hammock and... - VAREP - Treasure Valley, ID Facebook Log In VAREP - Treasure Valley, ID's Post VAREP - Treasure Valley, ID is in Boise, ID, United States . April 16, 2024 · Shared with Public THANK YOU, Danny Hammock and Boise Home Inspections for being our next ANNUAL Step and Repeat Logo Sponsor!!!! Do you want to find out how to get your logo on the Step and Repeat for a year and get two months FREE???? Reach out to Melissa Ethridge TODAY!!!!! DEADLINE IS THIS FRIDAY TO MAKE IT ON MAY'S!!! All reactions: 15 4 comments Like Comment Most relevant Jenn Abeyta Look a
Spe... - Red White and Blue Festival - Mountain Home, Arkansas Facebook Log In Red White and Blue Festival - Mountain Home, Arkansas's Post Red White and Blue Festival - Mountain Home, Arkansas June 16 at 7:00 AM · Shared with Public Special thanks to our Red Sponsor, Baxter Health , for their continued support of the 26th Annual Red, White & Blue Festival! As a cornerstone of healthcare in our region, Baxter Health is dedicated to improving the health and well-being of our community every day. Their commitment extends far beyond the walls of their facilities, supporting events and in
VULTURE — Barbara Marcel --> "> ︎ Recent Exhibitions KLIMA BIENNALE WILDERNESS ALLIANCES MOTORES DEL CLIMA THE CHANGE IN PATTERNS A PARÁBOLA DO PROGRESSO AL CONJURO DE ESTE CODIGO WEATHER ENGINES GOLDEN TONE in WEIMAR and ERFURT UMBRALES CRITICAL ZONES FLUIDE REALITÄTEN BIRDS AND BUOYS SÜDSTELLIUM AGROPOETICS FIRE, FAÍSCA, FUNKE DISAPPEARING LEGACIES Work in Progress CONDOR LETTERS FROM SPIRAL TIME BRAZILIAN WOOD Projects SURARAS MARLENE VULTURE CINE LIANA HUMO SOBRE HUMEDALES GOLDEN TONE MANIOK REIBE ICH DIR, SCHWESTERCHEN HIGHWAY BR-163 CUIABÁ - SANTARÉM MERCADÃO 2000 FOREST FLAME SE
Dani Bach - BioFIT Speaker Skip to content December 10 th & 11 th , 2026 15 th edition MARSEILLE, FR Linkedin 0 items 0 items 0 items Main Menu Menu Discover BioFIT BioFIT at a glance Organisers Steering Committee BioFIT x MedFIT News Press & Communication kit Programme Conference sessions Pitch sessions Start-up Slams Research & Licensing Partnerships Animal Health Presentations Previous edition Partnering One-to-one meetings Networking evening BioFIT 2025 partnering platform Participants Who will you meet? Supporters / Media Previous edition Exhibition Exhibition fees 2026 Exhi … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not ove … } {title} Manage consent Cart Have a coupon ? If you have a coupon code, please apply it below. Apply coupon Your cart is empty! Return to shop Cart - €0.00 0 1 Scroll to Top
Instagram Instagram Log In Sign Up Close Never miss a post from scienceandnonduality_ Sign up for Instagram to stay in the loop. Sign up Log in scienceandnonduality_ • Follow More options scienceandnonduality_ 55w In The Eternal Song, Vandria Borari speaks with the weight of generations behind her. As a ceramic artist, activist, and Indigenous leader of the Borari people in Alter do Chão, Brazil, she names a truth of our history The first ones to arrive in her territory were male colonizers—men who brought violence wrapped in the promise of civilization. With them came not just weapons and law
Instagram Instagram Log In Sign Up Close Never miss a post from lifesciencecareerday Sign up for Instagram to stay in the loop. Sign up Log in lifesciencecareerday • Follow More options lifesciencecareerday 60w During the event, you will be able to choose between three activities: • The photobooth: add the perfect touch to your resume with a professional headshot. • A chat with a professional recruiter: for those with a clear idea of their career goals and who want to get a chance to talk to a professional working in the private sector. • iEvolve – discovering your career options: a workshop w
💙🇺🇸... - Red White and Blue Festival - Mountain Home, Arkansas Facebook Log In Red White and Blue Festival - Mountain Home, Arkansas's Post Red White and Blue Festival - Mountain Home, Arkansas 2d · Shared with Public A Special Thank You to Our Blue Sponsors! We would like to extend our sincere gratitude to all of our Blue Sponsors for their support of the 26th Annual Red, White & Blue Festival! Community events of this size and tradition are only possible because of businesses, organizations, and individuals who believe in investing in the place we call home. Please join us in tha
Press release: Pressure mounts to kick polluters out of climate talks - Corporate Accountability menu Sign Up --> Donate Monthly One-time Email address * Close Who we are What we do Get involved Read the blog Podcast Resources For media How we advance justice Water Climate Food Tobacco Democracy  The Black Collective 2025 Annual Report Sign Up Donate Monthly One-time November 3, 2022 Climate Press release: Pressure mounts to kick polluters out of climate talks On eve of COP27, more than 425 organizations demand governments finally safeguard UNFCCC from industry influence SHARM EL-SHEIKH, E
Saintfield Show - Thanks to Blue Cedar for the sponsorship... Facebook Log In Saintfield Show's Post Saintfield Show June 18 at 6:04 AM · Shared with Public Thanks to Blue Cedar for the sponsorship for this years show All reactions: 4 Like Comment
Vandria - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpo … tibodies & antibody-drug conjugates to treat cancer $146M CTI Life Sciences Fund , Advanced Biotechnologies Venture Fund ... & 16 others 71/100 232nd Vandria 2018 , Lausanne ( Switzerland ) , Series A Developer of in-vitro screening platform for drug discovery and development $30.7M ND Capital , Dolby Family Ventures & 1 others 58/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on Vandria 's competitor
Instagram Instagram Log In Sign Up Close Never miss a post from scienceandnonduality_ Sign up for Instagram to stay in the loop. Sign up Log in scienceandnonduality_ and vandriaborari More options scienceandnonduality_ 15w In a powerful moment from Katô: Dreams of Dark Earth, Vandria Borari speaks about the devastating impacts of colonization on Indigenous communities across the Amazon. She recalls how entire villages were decimated, how violence, displacement, and missionary rule forced her people to retreat deeper into the forest. Cultural practices, ceremonies, and languages had to be hidde
%PDF-1.6 %���� 1495 0 obj > endobj 1528 0 obj >/Filter/FlateDecode/ID[ ]/Index[1495 66]/Info 1494 0 R/Length 140/Prev 10853425/Root 1496 0 R/Size 1561/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�$�I0[ Dr���. �ILf�I �x�-&��I^$0�L���� ��D���H�6)�DjIF�E`���b��s@$�>�� >stream h��}Pwǟ�MBBI���jb%g�R��5�K��vB �Z`���� �Z��`řH}���/h}��� -�)�7�'M v쩵R�+�^�v7�z7ӛ�����$���{���ͳ;� (uC@h!H��Cl*�n��ϧ�$�In�!+B F��U,�(�D�J����z���vS����>�o� �V��TJh���V��)c�I��y��C9�vA���ēx�y��7�ة���?;&; G���J�=i� [��f�|��U��m��xC�z7_��=�u���}���.3��]�=�[Szq����v�c���� [vO�e� … }yn-6���{�wz`����֜a�����7������ '_ pV�� endstream endobj 1523 0 obj >stream application/postscript Greg Nielsen SBT-Logo-TM-4c-pos.eps Adobe Illustrator CS2 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 uuid:24EBF3E16E8511DA9E4086E538E29E18 uuid:24EBF3E26E8511DA9E4086E538E29E18 endstream endobj 1524 0 obj >>>/Subtype/Form/Type/XObject>>stream H�2P��*�2PAC�l.}�`��b.#=Cs#=#s csC= ] ��H�(�+�+� �n� endstream endobj 1525 0 obj >/ProcSe … ����J�`� �L|0�@��#���24��[w���AX������ �u� endstream endobj 3 0 obj >stream application/pdf LONZA_LOGO_MAIN-BLK 2021-01-28T18:30:46Z 2021-01-28T18:30:46Z 2021-01-28T18:30:46+01:00 Adobe Illustrator 25.1 (Windows) uuid:a3de2334-99ae-43ee-9bbd-741f79caa74a xmp.did:4b30f76e-9211-bb47-ab33-a3600ddfe9ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9963990e-1bd9-b545-9ca6-06946215f430 xmp.did:9963990e-1bd9-b545-9ca6-06946215f430 uuid:5D20892493BFDB11914A8590D31508C8 … 6215f430 2021-01-28T18:06:09Z Adobe Illustrator 25.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4b30f76e-9211-bb47-ab33-a3600ddfe9ba 2021-01-28T18:13:17Z Adobe Illustrator 25.1 (Windows) / Print AIRobin Document False False 1 134.166337 51.249506 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 227 6 19 CMYK Yellow RGB PROCESS 255 … ) 2024-01-31T09:39:48+01:00 2024-04-10T08:57:56+02:00 2024-04-10T08:57:56+02:00 application/vnd.adobe.photoshop 4 Coated FOGRA39 (ISO 12647-2:2004) xmp.iid:c6d133e2-6c37-4c43-a5c7-2d2003c911c9 adobe:docid:photoshop:cbdeaaad-f9b2-a14f-b3b0-3fa9427c4f33 xmp.did:31c8d117-0238-4925-9f3f-74244c25ee44 created xmp.iid:31c8d117-0238-4925-9f3f-74244c25ee4
startupticker.ch News Startupticker.ch | The Swiss Startup News channel News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout Wednesday, 24.04.2024 Teylor wird mit Übernahme zum digitalen Marktführer im europäischen KMU-Kreditmarkt 24.04.2024 13:39 Die in der Schweiz ansässige alternative Kreditplattform Teylor übernimmt die deutsche KMU-Finanzierungsplattform creditshelf. Diese Übernahme ermöglicht es Teylor, seine Vertriebskapazitäten erheblich auszubauen und die Produktpalette im Direct-Len … llion in B2B technology startups 23.04.2024 09:00 With the closing of its first fund, Swiss venture capital firm 14Peaks Capital with a portfolio of 11 startups, has secured new resources to inject in early stage software startups in fintech and future of work. The round was supported by a consortium of limited partners, consisting of influential High Net Worth Individuals and family offices spanning Europe and the United States. Financing Supporters Monday, 22.04.2024 Auneti … .2024 09:19 Taucherli-Chef Kay Keusen verkauft sein Unternehmen an die Princess Grant Holding AG in Zug. Keusen hatte seine Premium Swiss Chocolate GmbH 2015 gegründet. Bekannt ist das Unternehmen heute nicht mehr nur für seine Trinkschokolade, sondern auch für Bean-to-Bar-Tafelschokoladen. Financing Wednesday, 17.04.2024 Spicehaus Partners final
Instagram Instagram Log In Sign Up Close Never miss a post from dianeburko Sign up for Instagram to stay in the loop. Sign up Log in dianeburko • Follow Alter Do Chão, Para, Brazil More options dianeburko 145w On August 18, I was honored to meet with Vandria Borari and several of her family members, friends, and fellow artists at their home and collective art space in Alter do Chão. We talked with each other at length about our artwork, and about what we hope our work will accomplish in terms of environmental activism. My assistant Ella translated between Portuguese and English, with support f
Instagram Instagram Log In Sign Up Close Never miss a post from miartmilano Sign up for Instagram to stay in the loop. Sign up Log in miartmilano • Follow More options miartmilano 10w The wait is almost over! ⌛ A look behind the scenes as we put the final touches on the new edition of the fair. VIP and Press Preview: April 16, upon invitation Friday & Saturday: 11:30 AM – 8:00 PM Sunday: 11:00 AM – 7:00 PM ➡️ Tickets available online at www.miart.it 🎥 Video: @vitimatt / @nicola.gnesi_studio #miart #miart2026 @fieramilano Load more comments arte.libri.cultura 10w 😍😍🔥 Like Reply roberto.
Team – ND Capital Primary Menu Portfolio Team Contact Investor Login Team All Investment Team Specialists Aymeric Sallin Founder & Chief Executive Officer × Aymeric Sallin Founder & Chief Executive Officer [email protected] Aymeric founded +ND Capital in 2002. He discovered the nanotechnology world while conducting research between the Physics and Chemistry departments of EPFL in the 90’s. He was convinced that significant breakthroughs would arise at the nanoscale and extensive expertise would be required to differentiate science from science fiction. This was the foundation o … Swiss Academy of Engineering Sciences (2016). He received the “2007 NSTI Fellow Award” and “2012 EPFL Alumni” award. Aymeric holds a Masters in Physical Engineering from EPFL where he is still an active member of the SAB and Chairman of the alumni association. Eric Moessinger Partner × Eric Moessinger Partner [email protected] Eric joined +ND Capital in 2008 and was the first employee of our Silicon Valley office. He is focused on life sciences investments. Eric is cu … 2009. Before Rusnano, Kirill worked for four years at a Russian private equity fund and was in charge of several investments in logistics, pharmaceuticals, and technology. Kirill also worked in various positions as an engineer, consultant (Boston Consulting Group), and operational manager in Korea, U.S., U.K., and Russia. Kirill holds a Masters in Computer Science from the Electrotechnical University of St. Petersburg as well as an MBA from INSEAD, France. Peter Liddiard Chi … y, with a focus on private equity and hedge funds. She spent 8 years working in fund administration and 5 years in audit working for PricewaterhouseCoopers in Grand Cayman and for KPMG in Cape Town. Alison qualified as a chartered accountant in South Africa and is a member of the South African Institute of Chartered Accountants and the Cayman Islands Institute of Professional Accountants. She holds a Bachelor of Business Science (Finance Honours) and Postgraduate Diploma in A … m the Federal Institute of Technology in Lausanne (EPFL). He did a Postdoctoral fellowship at Oak Ridge National Laboratories (USA). Carl Pabo Advisor × Carl Pabo Advisor [email protected] Carl joined +ND Capital in 2008. His research in biophysics made him a world leader in issues involving the structure and design of DNA-binding proteins. Dr.
About the 17th Annual European Life Sciences CEO Forum SachsForum SachsForum EVENTS: Upcoming Events > 1st EHIS Forum 26th BEF Forum 10th NIF Forum Recent Events > 2nd OCIF > POST 2nd OCIF Participants > Attendees Investors Presenters Sponsors Supporters 19th ELSF > POST 19th ELSF Participants > Attendees Investors Presenters Exhibitors Sponsors Supporters 1st ENIF > POST 1st ENIF Participants > Attendees Investors Presenters Sponsors Supporters 9th NIF > POST 9th NIF Participants > Attendees Investors Presenters Sponsors Supporters 11th OIF > POS … Partner, Quadrille Capital Georgia Frost, Senior Associate, Dementia Discovery Fund - SV Health Investors LLP Göran Forsberg, CEO, Cantargia AB Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting Jesus Baena, BD&L Transactions Director, Novartis AG Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc. Jonathan Tobin, Partner, Brandon Capital Josua Jordi, Co-Founder & CEO, EraC … edPartners AG BioMedVC AG Bioqube Ventures BlackRock bmp Ventures AG BOHE Angel Fund Boostrap Europe Bpifrance Brandon Capital Breslin AG Business Angels Switzerland CARMA FUND Management GmbH Cathay Health CEBINA Bridge Capital Convergence Partners DeBere Capital Partners Debiopharm International S.A. Delin Ventures Ltd. Dementia Discovery Fund - SV Health Investors LLP Digital Networks Plc. S.r.l. ESC Advisors Evoleen Forbion Forty51 Ventures Forty51 Ventures AG Fraser Fina … Ventures HBM Partners AG High-Tech Gründerfonds Management GmbH Indaco Bio Fund Innovestor Life Science Ltd. Intermediate Capital Group PLC IPF Partners Jeito Capital Johnston Associates, Inc. JP Morgan Kinled Holding Limited To View All - Click Here Sachs Associates Switzerland AG ​ ​ Aeschenvorstadt 4 Basel | CH-4501 ​Switzerland ​ Sachs Associates Ltd. ​ ​ 3rd floor, 89-90 Paul Street London | EC2A 4NE ​United Kingdom T: + 44
Vandria SA has come so far since we first met the small but mighty team (named Amazentis at the time) in 2019. Stellar team to work with. Excited to see what comes next, Chris RINSCH! | David Placek LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your
Biogen Acquires Apellis Pharmaceuticals for $5.6B, Adding EMPAVELI and SYFOVRE | Jack Shuang Hou posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Dolby Family Ventures | Portfolio Portfolio Philosophy People News Portfolio Our portfolio companies are addressing complex science and engineering challenges across the life sciences and technology fields. All All Life Sciences Technology Exits Precision Neuroscience Funding a diversity of approaches to complex neuroscience challenges across neurodegeneration, psychiatry and neurotech. Our core focus is disease-modifying treatments for Alzheimer’s Disease and Depression, but given the common and converging nature of underlying etiology, we fund across the spectrum of neuro disorders. Neurodeg … technology into “smart” implements capable of autonomously managing fertilizer application resulting in cost savings, increased yield, and reduced runoff. Active Soil Action Soil Action's sensor and AI-driven platform delivers real-time soil chemistry analysis — on-tractor, in-the-field — transforming variable rate technology into “smart” implements capable of autonomously managing fertilizer application resulting in cost savings, increased yield, and reduced runoff. Ac
Instagram Instagram Aanmelden Registreren Sluiten Mis nooit meer een bericht van ohshprojects Registreer je bij Instagram om op de hoogte te blijven. Registreren Aanmelden ohshprojects en bijanka_bacic Münster Meer opties ohshprojects Geverifieerd 33 w. This week we’re sharing OHSH exhibitor Bijanka Bacic’s exhibition Beyond the Frame, Between the Lines at WestLotto, Münster, presented alongside works by Peter Brüning, Charles Hinman, and Ernst Wilhelm Nay. Curated around Bacic’s recent paintings and three speculative letters written by the artist, the exhibition situates contemporary abstract
Instagram Instagram Log In Sign Up Close Never miss a post from elizabethxibauer Sign up for Instagram to stay in the loop. Sign up Log in elizabethxibauer Verified • Follow MNAC Bucharest More options elizabethxibauer Verified Edited • 168w Exciting news for Cătălin Marius Petrișor Hereșanu whose work has been acquired by MNAC – The National Museum of Contemporary Art, Bucharest, Romania. The work is now part of the MNAC permanent collection and is currently exhibited with other artworks recently acquired by the museum. The exhibition is called Puls 22 and is showing until October 1st 2023. T
Vandria • Biopôle Home Community Overview Life sciences companies Research institutes Stories Spaces Overview Office spaces Laboratory spaces Services & Amenities Programmes Overview Biopôle Investment Programme Vanguard Accelerator Corporate Partnerships Careers Overview Postgrad Consulting Programme Master’s internships Biopôle’s podcast Jobs About Biopôle SA Campus Region History Impact Annual Review News Stories Events MyBiopôle News Stories Events MyBiopôle Home Community Overview Life sciences companies Research institutes Stories Spaces Overview Office spaces Laboratory space
Swiss biotechs display their innovations at BIO 2026 in San Diego News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capita … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout Swiss biotechs display their innovations at BIO 2026 in San Diego Support Please login or register 19.06.2026 The BIO International Convention 2026 will take place from June 22 to 25 in San Diego, California. The swisstech pavilion features 21 leading Swiss startups. The event provides companies with a platform to showcase their innovations and network with a global aud … er to use the awards follow feature Highlights Abionic SA Top 100 Swiss Startup Award 2011 Top 100 Swiss Startup Award 2012 Top 100 Swiss Startup Award 2013 Top 100 Swiss Startup Award 2014 Top 100 Swiss Startup Award 2015 Winner Venture Kick Highlights Aukera Therapeutics GmbH Innosuisse Certificate Top 100 Swiss Startup Award 2025 Winner Venture Kick Highlights BioVersys AG Innosuisse Certificate Top 100 Swiss Startup Award 2011 Top 100 Swiss Startup Award 2012 Top 100 Swis … Swiss Startup Award 2011 Top 100 Swiss Startup Award 2012 Top 100 Swiss Startup Award 2013 Winner Venture Kick Highlights InSphero AG Innosuisse Certificate Top 100 Swiss Startup Award 2011 Top 100 Swiss Startup Award 2012 Top 100 Swiss Startup Award 2013 Top 100 Swiss Startup Award 2014 Winner Venture Kick Highlights IsoSpec Analytics SA Winner
Vandria’s series A funds spur development of mitophagy inducer | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscap
Homburger advised Hevolution Foundation on its Series A investment in Vandria SA – Legal Developments Skip to content Menu Home Legal Developments Press Releases Rankings Profiles GC Powerlist Events GC Magazine fivehundred Comparative Guides In-House Lawyer Webinars About Homburger advised Hevolution Foundation on its Series A investment in Vandria SA October 28, 2024 > Switzerland > Homburger | View firm profile The Hevolution Foundation and other investors provided additional funding in a Series A round totaling USD 30.7 m. Vandria discovers and develops novel small molecules th
Company profile from Vandria SA on jobup.ch Skip to content jobup.ch Navigation logo Find a job Explore companies Skip to content Salary estimator Recruiter Area Français English Login Find a job Explore companies Skip to content Salary estimator Recruiter Area My account Login Don't have an account yet? Sign up Select Language Français English Vandria SA Write a review Follow Overview Jobs (0) Reviews Vandria is a biopharmaceutical company that develops best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases in the fields of muscle- and CNS diseases with
Vandria SA Seeks Series B Financing for Alzheimer's Disease Trials | FirstWord Pharma posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … ased rejection rates, more missed review deadlines, and a temporary halt on new application submissions, several breakthrough therapies still secured approval in 2025. One of the most significant was Komzifti, developed by Kura Oncology, Inc. , now the only once-daily treatment approved for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). 👇 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝘁𝗲𝘅𝘁 𝗳𝗿𝗼𝗺 𝗿𝗲𝗰𝗲𝗻𝘁 𝗱𝗮𝘁𝗮: 🔵 In a Phase 2 trial, Komzif
Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football For … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 6h 27m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 6h 27m FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3192 -0.0006 -0.04% GBP/EUR 1.1603 +0.0006 +0.05% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,034.00 -13.60 … ndria and Amazentis, senior partner at ND Capital, Chairman of Novartis Venture Fund and board member of Nestlé, Logitech, and PolyPeptide Group. CEO Klaus Dugi, MD, joined Vandria in 2021 having spent 18 years in the pharma industry. He brings two decades experience in the pharma industry including more than eight years as Chief Medical Officer at Boehringer Ingelheim and Ferring where he has overseen the development, approval and launch of four $1bn+ blockbuster drugs. He i
Vandria SA bags CHF18m in Series A financing - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ X/Twitter This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. LinkedIn This field is for validation purposes and should be left unchang
25th BEF Presenters SachsForum SachsForum EVENTS: Upcoming Events > 1st EHIS Forum 26th BEF Forum 10th NIF Forum Recent Events > 2nd OCIF > POST 2nd OCIF Participants > Attendees Investors Presenters Sponsors Supporters 19th ELSF > POST 19th ELSF Participants > Attendees Investors Presenters Exhibitors Sponsors Supporters 1st ENIF > POST 1st ENIF Participants > Attendees Investors Presenters Sponsors Supporters 9th NIF > POST 9th NIF Participants > Attendees Investors Presenters Sponsors Supporters 11th OIF > POST 11th OIF Participants > Attend … and adaptive immune systems.​ www.immuneonco.com KHAN Technology Transfer Fund KHAN is an early-stage life sciences venture fund series with a mission to create value through collaborative drug discovery partnerships with leading academic innovators across Europe. The fund focuses on first-in-class therapies targeting areas of high unmet medical need and significant market potential. KHAN benefits from privileged access to cutting-edge scientific research from the … m the Max Planck Society and other top-tier European academic institutions. The fund is managed by Khanu, a world-class team with deep expertise in drug discovery and venture investing. Through its strong partnership with the state-of-the-art Lead Discovery Center in Dortmund, Germany, KHAN achieves a remarkably low attrition rate and delivers highly efficient early-stage investments. www.khanu.de Oryzon Genomics, S.A. [​BME: ORY] A public clinical-stage biopharma … tion. Expanding into hematological indications: sickle cell disease (PhIb trial application approved by EMA), essential thrombocythemia (in prep). www.oryzon.com/en Sen-Jam Pharmaceutical Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care Sen-Jam Pharmaceutical is pioneering a revolutionary approach to inflammatory and metabolic disorders with our proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) technology. By working with the body’s inna … e it is expected that we only need 50-100 more patients in a Phase III study to apply for market approval. We are building a syndicate now and are looking for the final partner. Will you join us and give hope to the Retinitis Pigmentosa patients? www.aldertx.com AM-Pharma B.V. AM-Pharma, a private biotech company based in Utrecht, the
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life? Can Saudi Arabia’s billions unlock the secrets to longevity? Jump to home page Jump to navigation Jump to horizontal navigation Go to language selection Jump to content The Swiss voice in the world since 1935 Home About us Search Sections Geopolitics Democracy Science Swiss Identity Economy Swiss Abroad Latest News Swiss Films Videos Podcasts Debates Special Reports Opinions Newsletters Ask Swissinfo Guide to Switzerland Switzerland How-To Education in Switzerland Tourism Trends Follow us Why you can trust Swissinfo en … oved and the high risk of failure have deterred most pharma giants and academic grant providers. Now, Saudi Arabia is throwing it a lifeline. Listen to the article Listening the article Toggle language selector Select your language Close English (US) English (British) Generated with artificial intelligence. Listening: Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life? Close Share This content was published on July 3, 2025 - 09:00 13 minutes Jessica Da … e-largest backer of the initiative, bankrolling $40 million of the $101 million prize money. “Ageing is the climate change crisis of human biology,” said William Greene, a US-trained physician and entrepreneur who is now the chief investment officer at Hevolution. “We’re living longer, but we’re not living more healthily. In fact, the number of years that we live with debilitating chronic disease has accelerated and expanded even as we live longer.” The lack of large-sc … cal trial design,” said Sergey Jakimov, a founding partner at longevity venture fund LongeVC. “People have been investing in shiny theses like curing ageing. That’s a great idea, but it doesn’t work for venture capital.” >> Read here about the rise of longevity clinics in Switzerland More More Healthcare innovation Longevity clinics: modern-day snake oil or the key to healthy ageing? This content was published on May 2, 2025 Scientists have yet to find the elixir of lif … and where their money comes from,” said Klaus Dugi, CEO of Vandria. “We want to apply the money we receive to address unmet medical needs and help patients live better lives.” Although Hevolution initially took a high-profile approach, it has become largely silent over the past few months. The last call for grant applications published on the fou
Vandria: 30,7 Mio. US-Dollar gegen altersbedingte Krankheiten - mit CEO Klaus Dugi ~ Startup Insider Podcast Podcast-News Alle Podcast-News Meldungen Berichte Kommentare Service-News Technik NAPS - Neues aus der Podcast-Szene Podcast Finde Podcasts Podcasts finden Podcast-Tipps Podcast-Charts Podcast-Verzeichnis Suche Podcast-Kategorien Kategorien-Übersicht Comedy Computer Englisch Freizeit Geschichte Gesellschaft Gesundheit Hörbücher Jugendliche Kinder Kunst Musik Religion Sexualität Unterhaltung Welt Wissen Wissenschaft Zuhause Mache Podcasts Podcasts machen Podcast-Wissen Podcasting-FAQ Pod … aus Luft, Pilz & Esel – warum Europa zu langsam ist | Nadine Geiser (World Fund) & Peter Schmetz (Vorwerk Ventures) 39 Minuten vor 1 Woche SpaceX-IPO, Bewertung & das Elon-Musk-Premium – Lukas Leitner (Drumbeat Capital) 33 Minuten vor 1 Woche In Podcasts werben Schalte jetzt Werbung in Podcasts. Alle Episoden anzeigen Kommentare (0) Melde Dich an, um einen Kommentar zu schreiben. Abonnenten Jetzer Erlensee 15 15 0.5x 0.75x 1x 1.25x 1.5x 1.75x 2x --> Episode teile
CEO of Vandria on Beyond Biotech Podcast | Vandria SA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
--> Klaus Dugi Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animals Invest … cer at Vandria Klaus Dugi is CEO of Vandria and Chief Medical Advisor at the VC Fund Limani Partners. Klaus is also a Board member at AOBiome Therapeutics, Ferring Ventures, Notify Therapeutics, and Cytoki. Klaus spent 18 years in the pharmaceutical industry with Boehringer Ingelheim and Ferring Pharmaceuticals, including 8 years as CMO. Klaus oversaw the development, approval and launch of several medicines including four which have achieved blockbuster status. Klaus was a P
Base to Base biotech podcast 4…–Base to Base Biotech – Apple Podcasts Search Home New Top Charts Search 9 January 54 min Base to Base biotech podcast 41: Eyes, mitochondria and a growing hub Base to Base Biotech Play This week, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we have a conversation about mitochondria, with the CEO of Vandria, Klaus Dugi, and there’s also a short discussion about GoCo Health Innovation City in Gothenburg, Sweden, with Moa Dicksdotter, Partnership and Ecosystem. Times: 02:35 Vandria 20:03 GoCo Health Innovation City 25:54 Oculis Looking to the ey
Central Nervous System Collaboration and Licensing Deals 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptio … utics Barrow Neurological Institute Base4 Biotechnology Baszucki Brain Research Fund Battelle Beacon Biosignals Beam Therapeutics Beijing InnoCare Pharma Belay Diagnostics Belharra Therapeutics BenevolentAI Benuvia Therapeutics Be The Match BioTherapies Beth Israel Deaconess Medical Center Bexorg Bexson Biomedical Bial BigHat Biosciences BioArctic AB biOasis Technologies BioAxone BioSciences Biobeat Biocept BioCircuit Technologies Biocodex Biocytogen BioDelivery Sciences Biof … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … ation and Licensing Deals 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Lonza partners with Exogenus on EVs | Renata Collazo, MS, MBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Link … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology
Central Nervous System Collaboration and Licensing Deals 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptio … utics Barrow Neurological Institute Base4 Biotechnology Baszucki Brain Research Fund Battelle Beacon Biosignals Beam Therapeutics Beijing InnoCare Pharma Belay Diagnostics Belharra Therapeutics BenevolentAI Benuvia Therapeutics Be The Match BioTherapies Beth Israel Deaconess Medical Center Bexorg Bexson Biomedical Bial BigHat Biosciences BioArctic AB biOasis Technologies BioAxone BioSciences Biobeat Biocept BioCircuit Technologies Biocodex Biocytogen BioDelivery Sciences Biof … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … ation and Licensing Deals 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
About Us | SpiroChem About Us | SpiroChem Submit request REQUEST A QUOTE Enter your contact information Search Enter what you are looking for Search by keyword. Search* Submit --> Discovery Computational Chemistry Medicinal Chemistry --> Computer-aided Drug Design Hit Validation Hit to Lead Lead Optimization Hit/Fragment Expansion Linker Design Properties Optimization SAR Elucidation Bioisosteric Replacement Strategies IP Evaluation Patent Filing New Modalities --> Macrocycles ADCs Degraders Radioligand Covalent Inhibitors Drug Conjugates OLN's Fully Integrated Services --> Our Expert Partner … ideas for new synthetic routes and aggressively explored each of the ideas for application to a very challenging structural motif that required a broad understanding and good command of asymmetric methodologies. In addition to generating and applying new ideas, they were also quite successful at making measurable improvements to existing synthetic processes. They are reliable and productive. All meetings went as scheduled and were always strongly supported with detailed upda … cal prowess, coupled with their creativity in problem solving, led to the swift proposal of rational alternatives to circumvent synthetic complications. It was a pleasure working with SpiroChem and I would recommend their suite of services to anyone seeking unparalleled excellence in the area of late-stage functionalization. Ryan Stites, Principal Research Scientist Our collaboration with SpiroChem has been extremely positive and productive. We had the pleasure of working wit
Logitech Canada, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Logitech Canada, Inc. Subsidiary Company | Canada | www.logitech.com Subsidiary Company | Canada | www.logitech.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Logitech Canada, Inc. Login to view more data 0 Patents (Medical) associated with Logitech Canada, Inc. Login to view more data 5 News (Medical) assoc … ndria and Amazentis, senior partner at ND Capital, Chairman of Novartis Venture Fund and board member of Nestlé, Logitech, and PolyPeptide Group. CEO Klaus Dugi, MD, joined Vandria in 2021 having spent 18 years in the pharma industry. He brings two decades experience in the pharma industry including more than eight years as Chief Medical Officer at Boehringer Ingelheim and Ferring where he has overseen the development, approval and launch of four $1bn+ blockbuster drugs. He i … pment and expansion of the process, which received a Scientific and Engineering Award from the Academy of Motion Pictures Arts and Sciences in 2016. He is responsible for integrating additive manufacturing technology with LAIKA’s production processes, which are used on the company’s sixth feature film, Wildwood. Nicholas Jacobson, a member of the translational research faculty at the University of Colorado Anschutz Medical Campus, is trained as both an architect and computati … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
%PDF-1.6 %���� 6269 0 obj > endobj 6331 0 obj >/Filter/FlateDecode/ID[ ]/Index[6269 95]/Info 6268 0 R/Length 241/Prev 12144960/Root 6270 0 R/Size 6364/Type/XRef/W[1 3 1]>>stream h�bbd```b`�4��g@��U�� Dz��H�� ��2�d������H� �x#�����|b�_ b��� �&�� ��L>��$?X��^ f��l R�D �If�i�K&��=�@�Y*\�Q��- �e� W���H2=p�٧�H��`��jD���r,� v�m��.��q�x.���}�&/�U^��r ���r�zp2���?e~0012H��D�bC����J�@�N?/S endstream endobj startxref 0 %%EOF 6363 0 obj >stream h��T�SW ~˒ �ـN�B�m.����`cQ����R�f��F�Uhq,����h(G� R�zB �֗�?|��U��5�W���7�kMr�2�uU���lԝ֮wV�A3DUr��b�EA��A�^c��,z�� … -4ac3c6197223 xmp.did:05801174072068119457BA3D942E5D2A proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Macintosh) / 2019-04-18T08:39:58+02:00 saved xmp.iid:1180a365-4c3a-479d-8ffc-04212828cb4b 2020-04-06T14:14:10+01:00 Adobe Illustrator 24.1 (Macintosh) / application/postscript Ed Gover Logos on front cover.eps Adobe PDF Library 11.0 False 1 False True 211.500161 42.412887 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 … -4ac3c6197223 xmp.did:05801174072068119457BA3D942E5D2A proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Macintosh) / 2019-04-18T08:39:58+02:00 saved xmp.iid:1180a365-4c3a-479d-8ffc-04212828cb4b 2020-04-06T14:14:10+01:00 Adobe Illustrator 24.1 (Macintosh) / application/postscript Ed Gover Logos on front cover.eps Adobe PDF Library 11.0 False 1 False True 211.500161 42.412887 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 … s://cairographics.org) 2020-04-07T15:08:48Z endstream endobj 6298 0 obj >stream application/postscript SNF_Standard_alle_rgb mirari 2021-09-08T08:31:19+02:00 2021-09-08T08:31:19+02:00 2021-09-08T08:31:19+02:00 Adobe Illustrator CS5 xmp.iid:444CF735132068118083D3D425D5F780 xmp.did:444CF735132068118083D3D425D5F780 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:3F4CF735132068118083D3D425D5F780 xmp.did:3F4CF735132068118083D3D425D5F780 uuid:5D20892493BFDB11914A8590D31508C … 83D71674C5ACA4 2021-08-09T14:06:04+02:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:0089DB9C0D2068118083F0D564AEB8D7 2021-08-09T
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
#agerelated #sarcopenia #cuore #mplusconsortium #mitochondria #muscleresearch #innovation #collaboration #eurostars | Vandria SA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t
Neurodegenerative disorders - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Ce … pipeline of SARM1 inhibitors. The financing, led by The Column Group, is set to fund the development of Nura Bio’s clinical pipeline, including the Phase Ib/IIa study of NB-4746, an oral, brain-penetrant SARM1 inhibitor. NB-4746 has… Read More 24 June 2026 #Business & Investment #News #Alzheimer's #Monoclonal antibodies #Neurodegenerative disorders #Neuroscience Refining, not abandoning, the amyloid hypothesis: Precision medicine after the Cochrane review Susan Abu
Vandria SA - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 17 Feb 2026 Vandria SA Holding Company | 2021 | Switzerland | < 10 | www.vandria.com Holding Company | 2021 | Switzerland | < 10 | www.vandria.com Last update 17 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Digestive System Disorders Small molecule drug Chemical drugs Disease domain score A glimpse into the focused therapeutic areas No Data T … -in-human clinical trial of its lead candidate VNA-318, supporting its possible application in treating Alzheimer’s disease (AD). VNA-318, a central nervous system (CNS) compound, is an orally bioavailable small molecule designed to target a novel protein associated with several human diseases. The treatment is currently being developed as a therapy for AD, but its broad mode of action may give it the potential to treat other diseases of the CNS in future. New results from th … parate closes of its series A, Vandria is aiming to raise more money in 2026 to fund not only VNA-318, but to also progress its preclinical pipeline of compounds in non-CNS indications such as muscle, lung and liver diseases. Phase 1 Phase 2 Clinical Result 08 Feb 2024 · www.biospace.com Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle Vandria is advancing a portfolio of mit … ress age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1.1M (CHF 1.0M) to support mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program LAUSANNE, Switzerland , Feb. 08, … research granting agencies is validation of Vandria’s scientific approach. The grant, totalling CHF 2.5M, is the second awarded to Vandria by Innosuisse and will support the early clinical development plan for the lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s
Union County... - Union County Sheriff's Office, Monroe, NC Facebook Log In Union County Sheriff's Office, Monroe, NC's Post Union County Sheriff's Office, Monroe, NC Verified account June 3, 2025 · Shared with Public Union County Sheriff’s Office Celebrates Employee Milestones This week, Sheriff Eddie Cathey welcomed five employees to the Union County Sheriff’s Office family during a brief ceremony. During the ceremony, our newest employees were administered their oaths of office in front of family, friends, and their new UCSO co-workers. The UCSO welcomed Detention Office … in your law enforcement career, check out our employee benefits and complete an application at the website link below. https://www.governmentjobs.com/careers/unionsheriff +4 All reactions: 441 41 comments 8 shares Like Comment Most relevant Melinda Caudle Congratulations 1y Blue Shield Tactical LLC Congratulations 1y Denise Austin Congratulations JR and everyone 1y 1 Betty Simpson Congratulations to all!! 1y Cindy McGee Needham Congratulations to JR and all the rest of the 1y
Vandria seeks series B funding to advance Alzheimer's candidate into Phase II | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Advisors – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Science + Clinical We are supported by world class scientists and medical professionals. Scientific Advisors Johan Auwerx, MD, PhD Johan Auwerx, MD, PhD Dr. Johan Auwerx is a pioneering scientist and co-founder of Vandria. As head of the Laboratory of Integrative Systems Biology at the EPFL, he has significantly advanced research in biomedicine, with an h-index of over 160. Johan has also founded and advised multiple biotech companies, includ … years of experience and 100+ publications on neurodegenerative diseases and the application of gene therapy in this field. As Head of the Bertarelli Gene Therapy Platform at EPFL and co-founder of Avrion Therapeutics, he continues to push the boundaries of gene therapy research, in particular for motoneuron diseases such as ALS. Bernd Sommer, PhD Bernd Sommer, PhD Dr. Bernd Sommer is a seasoned leader in neuroscience, having led Alzheimer's and neurodegeneration research unit … nse. Subsequently, his leadership also shaped early-phase clinical research and application of biomarkers in neuropsychiatric disorders. Richard Keefe, PhD Richard Keefe, PhD Dr. Richard Keefe is an Emeritus Professor of Psychiatry at Duke University and a leading expert in cognitive methods for psychiatric research. He has published over 300 scientific papers and co-founded VeraSci, where he served as CEO. Dr. Keefe has contributed to several landmark NIMH studies, solidifyi
%PDF-1.7 %���� 1220 0 obj > endobj 1242 0 obj >/Encrypt 1221 0 R/Filter/FlateDecode/ID[ ]/Index[1220 38]/Info 1219 0 R/Length 101/Prev 3669643/Root 1222 0 R/Size 1258/Type/XRef/W[1 2 1]>>stream h�bbd``b�^$�~ ƽ@�EH�> � �D܄/A��@��D��\�@�GH��� �y @�>d�5 �$�Z�YB�,F�����?�fg endstream endobj startxref 0 %%EOF 1257 0 obj >stream b� �bb�* Ϳu� �� o�2�9�p-���Cfv\�`E��iqwh��Z���W ��[ �ۉc���L��H��4%�Isf��f,�vɼ�{�q=���[x�/�cE�'�:��2�R�P� ��`�ء+�O�`H�G�|� ? �� ��� v�U�~yb����_�� b|S�^�u��E{�i+��SCfV:&Z�s�9��BJD��\D|j3ֳ�s3�p|3�fXd� �Aa �"��#������z_���Ō���E� cn~
Vandria Awarded €3.8M in Prestigious Innosuisse and --> Accessibility: Skip TopNav Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle February 08, 2024 03:00 ET | Source: Vandria Vandria Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive … t cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1.1M (CHF 1.0M) to support mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program LAUSANNE, Switzerland , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announced that it has been awarded two grants totalling €3.8M from Innos … research granting agencies is validation of Vandria’s scientific approach. The grant, totalling CHF 2.5M, is the second awarded to Vandria by Innosuisse and will support the early clinical development plan for the lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease. Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse. This grant follows … he CHF 2.5M non-dilutive funding from Innosuisse. This grant follows a research grant awarded two years ago, resulting in the generation of positive pre-clinical data in the indications of NASH and Alzheimer’s Disease. VNA-318 is a patent-protected, brain-penetrant, first-in-class mitophagy inducer on track to enter clinical trials in Europe in Q2 2024. Innosuisse is the Swiss Innovation Agency that helps to fund science-based pre-commercial projects of start-ups with signifi … cial projects of start-ups with significant innovation potential. The Eurostars grant, totalling €1.1M, to which Vandria adds €0.5M, is awarded to support mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program in collaboration with Prof. Olivier Benveniste of hôpital Pitié-Salpêtrière AP-HP, France, Biomeostasi
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
#partnering #investment #lifescienes #mitochonrialtherapeutics #neurodegenerativediseases #drugdevelopment #mitophagy | Vandria SA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … cted, mitophagy inducer this summer and we are already planning our series B to fund further trials and pipeline growth. If you’d like to meet up send us a partnering invitation or email us on [email protected] More information on our science and portfolio HERE www.vandria.com #Partnering #investment #lifescienes #MitochonrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy 19 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,30
%PDF-1.4 %���� 1 0 obj > endobj 5 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … 5�b��3 X1�;I ���[ Z3� ĵ�� �r @� HJ���g�`�w�BȐ�j�b�ĦB&��b,���Ն:?d���.��"�rfP��a d=8�����K'�ˉ=�Vr�/`@��F���w5�ǁ�s��ke�!�U Dn0�H݄Ag�^Bv�=;,\'�:�r�d!VI�Z�Q�d �I�Y-MW�1�����(G!D�7`����b$��z��Hq���;D�F��N��;�h�T�$��[�+�C����$�8��+ڟ4 3jB#x�Y�"q��!� � 3qR��Q� �CE�a �e��g��+n[�������u��%rV�iu-���\խ�d��wd���� l~�>o��W ���i��A����i�j����ĩ~�������\�/!4rL Ra�m(��i�j�(7;G}��@��Ȋ-R *Jg���"P D��"93e#�2& �E����^M֥�V���)��,�8�b���Ӣe�ȼ���eY����Lj4� … b\��ײw-���{�r��\�1���0���X��p��_�W7�����ƃ���ڈ8 {��p�{T\�\C?5b7Ƴ�|��H��dζ��RFp�#8� ���i�F$�W�&jA�������n��1�״���T�X�a��E�җ ���CcE �N�҉8�����$A����=7&[[v��F'��X���J�5JYׂ�}7{/R�}� /B^R�U�mL��N}����x��7d7{yi� ����R~&皟��ݶ 1���s�#�B��|Ne� ���䀻-W�js`ͩFW�$\�����:��~\µ�[}W � T�j)�/E�Iǁ�[۹���n�oƨ�2���K�����L�����( ~s��Ge Bt�;7�� l�Y�U�7F������� �}XI���� �V߽m��WA���+��G���wF�&�X�fD[�ZQ�(�ǦclI�rg�77��qU���{��l� ����J��t�4�.�|��֩L>���.��A����
Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle 8 February 2024 Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innos … ress age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1.1M (CHF 1.0M) to support mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program Lausanne, Switzerland – 8 Februa … research granting agencies is validation of Vandria’s scientific approach. The grant totalling CHF 2.5M is the second awarded to Vandria by InnoSuisse and will support the early clinical development plan for the lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease. Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from InnoSuisse. This grant follows a … he CHF 2.5M non-dilutive funding from InnoSuisse. This grant follows a research grant awarded two years ago resulting in the generation of positive pre-clinical data in the indications of NASH and Alzheimer’s Disease. VNA-318 is a patent-protected, brain-penetrant, first-in-class mitophagy inducer on track to enter clinical trials in Europe in Q2 2024. Innosuisse is the Swiss Innovation Agency that helps to fund science-based pre-commercial projects of start-ups with signific … cial projects of start-ups with significant innovation potential. The Eurostars grant totalling €1.1M, to which Vandria adds €0.5M, is awarded to support mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program in collaboration with Prof. Olivier Benveniste of hôpital Pitié-Salpêtrière AP-HP, France, Biomeostasis
Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development - Hevolution Foundation Navigation Skip to Content --> --> --> --> Events Global Healthspan Summit 2025 About News Science Grants Funding Opportunities Partnerships Investments Team Contact العربية News and Commentary 2 --> Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-31 … eases of the muscle, lung and liver. This investment aligns with our mission to fund innovations that help catalyse the shift from lifespan to healthspan so that everyone can live healthier lives for longer.” Sourav Kole, Managing Director, Dolby Family Ventures said, “Given the association of mitophagy to neurodegeneration and other disorders and Vandria’s robust preclinical dataset in showing neuroprotective effects and the potential to improve cognition, we are delighted t … non-dilutive funding: two Innosuisse grants to support VNA-318 and an Eurostars grant to support the generation of pre-clinical data for mitophagy drug candidates in Vandria’s muscle program. Klaus Dugi, CEO of Vandria, said: “I am delighted to welcome Hevolution Foundation and Dolby Family Ventures, alongside ND Capital, to support our transformation into a clinical stage company. This Financing will enable us to progress further in clinical development with runway from the
Contact – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Location + Details Contact [email protected] Linkedin Address Vandria SA Route de la Corniche 8 1066 Epalinges Switzerland Linkedin Linkedin Share on LinkedIn Scroll to top
Chris Rinsch PhD, MBA - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Chris Rinsch PhD, MBA Co-Founder & President at Timeline Nutrition Chris Rinsch PhD, MBA 's Executive Work History Current Co-Founder & President , Co-Founder & President Equilar on 04/15/2026 Timeline Nutrition Board Member , Board Me
Vandria - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization Vandria vandria.com Company Details Description Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. Industry Industrial Products & Machinery, Pharmaceuticals Location Lausanne, Switzerland Employee C … duated with an MD from the University of Muenster in Germany, and completed her residency and fellowship training in Psychiatry, Psychotherapy and Neurology at the Max Planck Institute of Psychiatry in Munich and obtained her habilitation degree at the Ludwig Maximilian University in Munich. She has extensive expertise and training in Neurosciences, Psychiatry, and Neurology, with a career spanning over 25 years in both academic research and Pharmaceutical R&D. Since join … duated with an MD from the University of Muenster in Germany, and completed her residency and fellowship training in Psychiatry, Psychotherapy and Neurology at the Max Planck Institute of Psychiatry in Munich and obtained her habilitation degree at the Ludwig Maximilian University in Munich. She has extensive expertise and training in Neurosciences, Psychiatry, and Neurology, with a career spanning over 25 years in both academic research and Pharmaceutical R&D. Since join
Pénélope Andreux PharmD, Ph.D. - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Pénélope Andreux PharmD, Ph.D. Chief Executive Officer & Board Member at Vandria Pénélope Andreux PharmD, Ph.D. 's Executive Work History Current Chief Executive Officer & Board Member , Chief Executive Officer & Board Member
Smith County - When Alexander Kaine Johnson stepped into... Facebook Log In Smith County's Post Smith County is with Robert Wilson. 321st District Court Judge, Smith County, Texas and 3 others . February 20 · Shared with Public When Alexander Kaine Johnson stepped into the 321st District Courtroom to be adopted on Friday, he was surprised to see about 45 fellow fifth graders from Bell Elementary School. Bell Principal Tamara Johnson and several teachers brought the group of kids to celebrate his adoption after a two-year-long process. Vandria and Tyrone Johnson adopted 11-year-old Cain Co
Vandria’s €3.8M collaboration with Catalyze - Catalyze Consulting Services Industries Funding Database Cases Our Company Insights Contact Your partner in innovation Fund Strategic Funding Advice Funding Applications Reviews & Resubmissions Loan & Venture Debt Tax Incentives Strategy Business Coaching Market Research Business Plans Feasibility Studies Outsourcing Workshops & Training Manage Project Management Financial & Portfolio Management Communication & Dissemination Invest Equity Investment Impact Investing Investor Readiness Programme Financial CFO as a Service Management Reporting Operat … ear Catalyze and Vandria collaborated towards Vandria’s CHF 2.5 million (€2.7M) grant from Innosuisse Start-up Innovation Projects and €1.1 million grant from Eurostars. The funding enables Vandria to enter the next stage of development for their two lead drug candidates. We heard from Pénélope Andreux, Chief Scientific Officer, about the importance of these projects, and her experiences working with Catalyze. The Vandria team outside their office in Lausanne, Switzerland, wi … e successful resubmission of the Eurostars project. “In the past I had tried to apply for Eurostars, but without the help of a group like Catalyze. It was a challenge, because this grant is a huge piece of work to write and to manage. I really saw the difference of Catalyze’s support during our resubmission to Eurostars.” The overall collaboration on SIP and Eurostars Shortly after working on the awarded Eurostars, Vandria and Catalyze collaborated on their SIP submission. Th … Vandria and Catalyze collaborated on their SIP submission. The CHF 2.5 million award made it two out of two successful collaborations between Catalyze and Vandria, in a highly effective partnership. Pénélope describes the collaboration, “First, people at Catalyze have delivered a high-quality work. Even though we worked on two different grants with different people, the quality was high across both proposals. Something I see overall with Catalyze is the quality of communicat … December 2025, the DONOR-PROTECT project was awarded a €3 million Consolidator Grant from the European Research ... Read more Asgard Therapeutics’ €2.5M EIC Transition project, Repro-TIL Asgard Therapeutics was awarded a €2.5 million grant by EIC Transition for the ‘Repro-TIL’ project, which will ... Read more Contact +31 020 7234400 or Send us
We appreciate the... - Moving Mountains Adaptive Program Facebook Log In Moving Mountains Adaptive Program's Post Moving Mountains Adaptive Program June 8 at 6:00 PM · Shared with Public We appreciate the support of Gold Sponsor MJ Electric All reactions: 12 1 share Like Comment
%PDF-1.4 %���� 1752 0 obj > endobj xref 1752 17 0000000016 00000 n 0000003242 00000 n 0000003389 00000 n 0000003427 00000 n 0000003908 00000 n 0000005122 00000 n 0000006265 00000 n 0000007511 00000 n 0000008680 00000 n 0000009742 00000 n 0000010807 00000 n 0000011882 00000 n 0000013038 00000 n 0000013827 00000 n 0003669986 00000 n 0003677226 00000 n 0000000636 00000 n trailer ]/Prev 21203312>> startxref 0 %%EOF 1768 0 obj >stream h��X}PT�������c��Y HA���}���4��V�����(��i�O�fM m-~TPׯ J �qj��c>4�.�+8�������1�;N��ݷ��1t�����{ι����] 0 � 0:�OB��G��q���L1Bl2`e��kA�-�d{��� &� � … ��N��3_Z�;ٌ*I1�RHI�d��$��?D��v�~|K)�2 �6�#E��&͡��&%H�4� ��>����aS/HR @?rfP�o�8�n� H��·�N^h�o�yJ4��k*�����NC�;��\8 �������q|�1��8�ڞ����Z��}/m�9E���)�N �e�a���q��Rㄺ ��Z��֧8�C�Q|�p��` ��� ����R���Kz�=\���H�@�Q�[�iyd�pheLq�� �`\���D�]a�T �}���.D�����II��e�YHx�Y��&�����8���?li� ���})h�K �cx���'�A�����Z~��q��É�-���r�Z��C���'֠�P#��Z^� �WV�I�b�+ �N�v@�cz,���=V� ��-�cɩ��9�� ���yz -.THu2�-_� C{�sLw=���o>G��X� S��X�~���I����l�^Ӫ���=f >��~?uj … PDFreactor(R) 11.6.12 (16335), Serial No: 4369, Licensed for: mms solutions ag application/pdf uuid:e0a5bb09-d1b5-47d6-9c6e-182dcda30a86 uuid:18b3c229-d83d-4fd5-abfe-bcdbdebe8fdb endstream endobj 1751 0 obj > endobj xref 0 1752 0000000000 65535 f 0003684902 00000 n 0003685455 00000 n 0003685561 00000 n 0003685667 00000 n 0003685773 00000 n 0003685879 00000 n 0003685985 00000 n 0003686091 00000 n 0003686197 00000 n 0003686303 00000 n 0003686410 00000 n 0003686516 00000 n 0003
Partnering – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Medicines + Health Partnerships and collaborations are central to our goal of bringing our pipeline of small molecule therapeutics to treat age-related and chronic diseases. Partnering We are seeking a pharma partner to support us in bringing VNA-318, our innovative, differentiated, well-tolerated once-daily oral drug, to patients with Alzheimer’s and other CNS disorders. Contact Us To discuss a potential collaboration, email info@van
Scholarship Endowment Funds Skip Nav Claflin University Menu Go to Search Search Search Our Site: Close Search About About Claflin Why Claflin History Location & Directions Offices & Services Leadership 2021-2026 Strategic Plan Sustainability at Claflin Employment Contact Us Directory Policies and Procedures Accreditation Why Claflin? Find out why a Claflin education is more than a means to a degree. Admissions & Aid Admissions & Aid How to Apply Plan a Visit Request Information Meet Your Admissions Counselor Tuition & Fees Financial Aid Accepted Students Parents Off … Claflin! Alumni & Giving Alumni & Giving Give Now Ways to Give FOCUS100 Scholarship Fund Honor Roll of Donors Outstanding Leaders Under 40 Alumni News & Events Claflin University International Alumni Association Alumni Spotlight Institutional Advancement Ways to Give Claflin is #1 in alumni giving among all HBCUs, thanks to you. Nissan Theatre Undergraduate Application Graduate Application Transcript Request Athletics Directory Contact Us Acade … istration Calendar Help Desk Bookstore Library Dining Panther Alerts Close Menu Apply Plan a Visit Request Info Virtual Tour Claflin University / Alumni & Giving / Ways to Give Scholarship Endowment Funds Allen G. Britt Endowed Scholarship Fund Greetings Family and Friends, As an alumnus of Claflin University and desiring to assist young people in their efforts to acquire a higher education in a Christian environment, I have established the Allen G. Britt Endowed S … hristian environment, I have established the Allen G. Britt Endowed Scholarship Fund at Claflin University in the amount of $25,000. I solicit your support in this worthy endeavor. Your contribution can be made online or in person via check or credit card. Please make your check payable to Claflin University. All donations are appreciated and are tax-deductible to the extent allowed by law. The Financial Aid Office of the University will select first-time freshmen recipients … ank you for your support of my request! - Allen G. Britt Steward Twins Memorial Scholarship Fund Greetings Family and Friends: Holiday Blessings! I, Vandria Steward, a former student of Claflin University’s Summer Science Enrichment Training Program in Math and Science (SSETP), desiring to assist young people in their efforts to acquire a h
%PDF-1.4 %���� 1 0 obj >/Contents [ 4 0 R ] /Rotate 0 >> endobj 5 0 obj > stream x���_PLQ ��j��b%M3�K̈́� s��s������;�fo��O>�KT*B��ؿ��)�&zo ? ����ߌ����𰐐��X>2.=!+3-!%9�pũ�����-E�7+� ��.l�j�鬨����" z�m�J�E�d*!*�J~�K��hu.�z7wzB�'Q�4�V��i��w�'Z/݄is��L4ot H5��{�~��K�' ��3�ŧ�ss���3�70hf07+|����"����._a�W�^�v�� ��[�&&m۞��cg殬���� ʷ -8f=~�da�Y�V|�|Ʌ�W�ʯ^��~���ʪ�{5�k >z�����E[��W�}�����_��~뱷=O�� .�N��_&�7�̔�� ��ʛ~h_`(;̦O��èD� ��pP�a Q��-֯a4��~T� 6��]˪�@CY�����VPv��#���:K��V��j�8�D��ǚl��Ϭ�3t8���ā�=[�F+'N�� > /Width 1392 /Height 180 /BitsPerComponent 1 /Length 8 0 R /Image … :6b3d22e4-07e9-0d0c-1d10-e1520f729d52 uuid:6b3d22e4-07e9-0d0c-1d10-e1520f729d52 application/pdf S45C-925011312290 endstream endobj 1039 0 obj 3843 endobj 1040 0 obj > endobj 1041 0 obj > endobj xref 0 1042 0000000000 65535 f 0000000016 00000 n 0001265850 00000 n 0000008022 00000 n 0000007763 00000 n 0000000204 00000 n 0000001231 00000 n 0000001250 00000 n 0000003554 00000 n 0000003574 00000 n 0000005634 00000 n 0000005655 00000 n 0000006947 00000 n 0000006968 00000 n 00000077
Vandria SA: Mitochondrial Therapies for Neurodegenerative Diseases | Sachs Associates posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si
%PDF-1.5 %���� 4355 0 obj > endobj xref 4355 59 0000000016 00000 n 0000005387 00000 n 0000005504 00000 n 0000006795 00000 n 0000007609 00000 n 0000008156 00000 n 0000008957 00000 n 0000008996 00000 n 0000009111 00000 n 0000009391 00000 n 0000009959 00000 n 0000010241 00000 n 0000010900 00000 n 0000011180 00000 n 0000011878 00000 n 0000012565 00000 n 0000012678 00000 n 0000013316 00000 n 0000013868 00000 n 0000014310 00000 n 0000014852 00000 n 0000015397 00000 n 0000015791 00000 n 0000016277 00000 n 0000016555 00000 n 0000017099 00000 n 0000017216 00000 n 0000017737 00000 n 0000018241 00000 n 0 … /ExtGState >>>/Subtype/Form>>stream H��w6PH.V0C��� > endobj 4403 0 obj >stream application/postscript Print (Benjamin R\303\266big) 2022-11-01T17:53:04+01:00 2022-11-01T17:53:04+01:00 2022-11-01T17:53:04+01:00 Adobe Illustrator 26.0 (Macintosh) xmp.iid:b3eb440b-7525-45f5-a42b-5ce225f8f7c9 xmp.did:b3eb440b-7525-45f5-a42b-5ce225f8f7c9 uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:9cd54644-8f17-49df-b57d-bd7bedeb6889 xmp.did:9cd54644-8f17-49df-b57d-bd7bedeb6889 uuid:5D2 … t;x�m�v� h����� Th���o�Gh )����ub��'��EЉ endstream endobj 5 0 obj >stream application/postscript This_is_Basel_Logo_final_SR 2020-10-06T09:40:20+02:00 2020-10-06T09:40:20+02:00 2020-10-06T09:40:20+02:00 Adobe Illustrator 24.3 (Macintosh) xmp.iid:4f81bcc6-2796-4389-99b4-010953125579 xmp.did:4f81bcc6-2796-4389-99b4-010953125579 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:b33d3a68-8315-f04b-b24a-24832c82630a xmp.did:574a500d-1587-4090-ab20-921ea5ba1e94 uuid:5D2089 … 9 2020-10-06T09:40:20+02:00 Adobe Illustrator 24.3 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator Print AIRobin Adobe PDF library 15.00 1 False True 24.834524 16.484655 Millimeters Black Standard-Farbfeldgruppe 0 Weiß CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Schwarz CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 CMYK Rot CMYK PROCESS 0.000000 100.00 … 0 90.000000 0.003100 0.003100 endstream endobj 6 0 obj > endobj 7 0 obj >stream application/postscript URL_Test_black J. Diethelm 2014-11-05T12:08:08+01:00 2014-11-05T12:08:08+01:00 2014-11-05T12:08:08+01:00 Adobe Illustrator CS6 (Macintosh) xmp.iid:048011740720681183D18039B4971674 xmp.did:048011740720681183D18039B4971674 uuid:5D20892493BFDB11914
Annual Report FY2025 - Corporate Accountability --> Toggle navigation Annual Report FY 2025 Letter Mission Highlights Community Financials Annual Report FY 2025 LETTER FROM THE Executive Director Dear friend, I'm no stranger to the front lines of the struggle between corporate power and the people. As a student in Mexico, I took part in battling the corporate takeover of our public university. I participated in movements challenging mining corporations and corporations supporting genocide. Over the years, I've seen people join together across race, class, and other differences to fight seeming … ch the School to Prison Pipeline documentary Spotlight: The Movement Solidarity Fund Powering the global movement to challenge corporate abuse Global movements are more important now than ever. To win, we need to make sure all of us have the resources we need. Through the Movement Solidarity Fund, we raise and redistribute financial resources to our partners and leaders on the front lines of corporate abuse. Together, we're helping sustain the global movement challenging corp … ies like Brazil to take legal action against Big Tobacco. Inspired movements to apply its groundbreaking measures to other deadly industries, from Big Polluters to food and beverage corporations to plastic polluters and beyond. As we celebrate this two-decade milestone, we can't forget that this deadly industry keeps profiting at the expense of our health and our lives. It's up to us to support governments around the world in harnessing the power of the treaty to make Big Tob … ts groups on the front lines of corporate abuse through the Movement Solidarity Fund. Your support is powering critical organizing across the globe to challenge corporate abuse. 14,000 14,000 people came back again and again to challenge corporate power, taking action multiple times this year. Our Allies Building deep solidarity and organizing hand-in-hand with activists across the U.S. and around the world is critical for building a movement that is strong enough to challeng … er privatizer Veolia — triggered such a crisis, the first step was clear: submit a request for a water line replacement. When the water authority denied her request, the second step was even clearer: organize. Bringing people together to take action is second nature for Gabby. "I grew up in the Black community, surrounded by folks who knew
ND Capital – Investing in Disruptive Technologies Primary Menu Portfolio Team Contact Investor Login Investing in Breakthroughs Who We Are +ND Capital (f.k.a. NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences. Our core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will be based on this convergence. We invest across the United States and Europe, and through our teams in Silicon Valley, Switzerland and the Cayman Islands, we can help our … Swiss Academy of Engineering Sciences (2016). He received the “2007 NSTI Fellow Award” and “2012 EPFL Alumni” award. Aymeric holds a Masters in Physical Engineering from EPFL where he is still an active member of the SAB and Chairman of the alumni association. Eric Moessinger Partner × Eric Moessinger Partner [email protected] Eric joined +ND Capital in 2008 and was the first employee of our Silicon Valley office. He is focused on life sciences investments. Eric is cu … 2009. Before Rusnano, Kirill worked for four years at a Russian private equity fund and was in charge of several investments in logistics, pharmaceuticals, and technology. Kirill also worked in various positions as an engineer, consultant (Boston Consulting Group), and operational manager in Korea, U.S., U.K., and Russia. Kirill holds a Masters in Computer Science from the Electrotechnical University of St. Petersburg as well as an MBA from INSEAD, France. Peter Liddiard Chi … y, with a focus on private equity and hedge funds. She spent 8 years working in fund administration and 5 years in audit working for PricewaterhouseCoopers in Grand Cayman and for KPMG in Cape Town. Alison qualified as a chartered accountant in South Africa and is a member of the South African Institute of Chartered Accountants and the Cayman Islands Institute of Professional Accountants. She holds a Bachelor of Business Science (Finance Honours) and Postgraduate Diploma in A
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Pipeline – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Breadth + Progress Novel target with strong genetic links to several age-related diseases underpins a broad pipeline with lead CNS asset VNA-318 advancing through the clinic. Pipeline VNA-318 Differentiation with Acute Plus Long-Term Effects Pre-Clinical Evidence Supports a Dual-Mode Cognitive Improvement with VNA-318 VNA-318 First-in-Human Trial Delivers Key Foundation to Facilitate Future Drug Development Partnering Find out more about part
VNA-318 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 02 Apr 2026 VNA-318 Last update 02 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms - Target - Action - Mechanism - Therapeutic Areas Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases Active Indication Alzheimer Disease Amyotrophic Lateral Sclerosis Cognition Disorders + [1] Inactive Indication - Originator Organiz … -in-human clinical trial of its lead candidate VNA-318, supporting its possible application in treating Alzheimer’s disease (AD). VNA-318, a central nervous system (CNS) compound, is an orally bioavailable small molecule designed to target a novel protein associated with several human diseases. The treatment is currently being developed as a therapy for AD, but its broad mode of action may give it the potential to treat other diseases of the CNS in future. New results from th … parate closes of its series A, Vandria is aiming to raise more money in 2026 to fund not only VNA-318, but to also progress its preclinical pipeline of compounds in non-CNS indications such as muscle, lung and liver diseases. Phase 1 Phase 2 Clinical Result 14 Dec 2023 · www.biospace.com Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform Vandria emerges from stealth announcing its $20.6M … ndria and Amazentis, senior partner at ND Capital, Chairman of Novartis Venture Fund and board member of Nestlé, Logitech, and PolyPeptide Group. CEO Klaus Dugi, MD, joined Vandria in 2021 having spent 18 years in the pharma industry. He brings two decades experience in the pharma industry including more than eight years as Chief Medical Officer at Boehringer Ingelheim and Ferring where he has overseen the development, approval and launch of four $1bn+ blockbuster drugs. He i
Science – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Science + Innovation Novel target underpinned by 15+ years of scientific research and innovation. Our Focus Vandria has identified a novel metabolic target that plays a key role regulating energy production within cells, enhancing overall efficiency. The target has strong genetic links to several human diseases, especially neurodegenerative diseases. With a focus on halting or slowing the progression of age-related diseases, we are developing
The #KidsFirst Team had a great Day... - Kids First Education Facebook Log In Kids First Education's Post Kids First Education June 10 at 1:57 PM · Shared with Public The #KidsFirst Team had a great Day 1 at MASSP in Biloxi! We are honored to serve as this year’s Platinum Sponsor and proudly sponsored the luncheon keynote speaker, Dr. Joe Sanfelippo. His message was inspiring and a powerful reminder of the impact Mississippi’s educational leaders have on students every day. Thank you to all MS administrators and leaders for your dedication to student success. We appreciate all that you do
#dayone #vandria #biotech #innovation #firstinclassdrug #scientificbreakthroughs #cellularhealth #mitochondria #frontierscience | Superlab Suisse LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl … field! This is made possible in part by a contribution from the National Growth Fund Program NXTGEN Hightech . #Bronkhorst #Biotechnology #CellTherapy #PersonalizedMedicine #Innovation #DutchInnovation 65 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Women TechEU 16,095 followers 8mo Edited Report this post Women TechEU Chapter meetups! 📍On 4 March, Women TechEU held its first Barcelona Chapter meetup during Mobile World Congress wee
Vandria's CSO and Head of BD at #BioEurope Spring in Milan | Vandria SA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … ive impairment as the first indication. We are already planning our series B to fund further trials and pipeline growth. If you are in Milan and want to meet up send us an invitation via the partnering system or email us on [email protected] Information on the conference HERE https://lnkd.in/eRdjEqv More information on our science and portfolio HERE www.vandria.com #Partnering #Investment #LifeScienes #BES2025 #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy 45 1 Comment … sis development, it will significantly aid future drug development.” During the application process in ODIN, Novo Nordisk proactively reached out to the academic team to express their interest in the project. Together with the other industry partner, they helped shape the final proposal – ensuring strong relevance and engagement from both sides. The FibroCard project is a great example of how ODIN projects can start as academic ideas and grow into collaborations that are valu … roving clinical outcomes for people living with PSP. Researchers are invited to submit a Letter of Intent by December 15, 2025, 5:00 p.m. (U.S. Eastern Time). 🔗 View full program details and application guidelines: https://lnkd.in/eFQ_bzFA #CurePSP #Biomarkers #BiomarkerDiscovery #Research #Neurodegeneration 10 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Matt Krebs 8mo Report this post ⚡New Energy for ALS & Parkinson’s? Meet the other NR
Vandria Announces $20.6M (CHF18M) Series A Financing Led by --> Accessibility: Skip TopNav Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform December 14, 2023 03:00 ET | Source: Vandria Vandria Vandria emerges from stealth announcing its $20.6M (CHF18M) Series A financing led by ND Capital Lead candidate VNA-318 is a clinic-ready, brain-penetrant, mitophagy inducer shown to improve memory and learning Potential for a range of CNS indications including cognitive impairment, dementia, Alzheimer’s an … ndria and Amazentis, senior partner at ND Capital, Chairman of Novartis Venture Fund and board member of Nestlé, Logitech, and PolyPeptide Group. CEO Klaus Dugi, MD, joined Vandria in 2021 having spent 18 years in the pharma industry. He brings two decades experience in the pharma industry including more than eight years as Chief Medical Officer at Boehringer Ingelheim and Ferring where he has overseen the development, approval and launch of four $1bn+ blockbuster drugs. He i
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease 2 December 2025 Results presented at the 18th Clinical Trials in Alzheimer’s Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel … o being tested in patients.” Vandria is planning to raise a Series B in 2026 to fund proof-of-concept Phase 2 trials. The global market for Alzheimer’s alone is estimated at $6 billion and is expected to grow at a CAGR of 12% to 2035, driven by an aging population, improved diagnosis, and a growing awareness and understanding of the condition and its implications. The planned Series B will also be used to progress Vandria’s pre-clinical pipeline of compounds in non-CNS indica
Media Centre – Vandria About Us Team Board of Directors Advisors Science Pipeline Partnering Media Centre News and Events In the News Contact Menu Menu News + Events Press Releases Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease 2 December 2025 Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer 18 December 2024 Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.
Vandria's VNA-318 Shows Promising Results in Alzheimer's Disease Trial | Vandria SA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Vandria announces topline results from Phase I trial of VNA-318 Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Se
Vandria at Biotech Showcase 2026 | Vandria SA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Co
#cns #muscle #liver #lung #cns #bio2025 #partnering #investment #cns #neurodegenerativediseases #drugdevelopment #mitophagy #mitochondria | Vandria SA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn
Vandria reports VNA-318’s first-in-human data in Alzheimer’s - Labiotech.eu Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? S